OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2
Lia Fiaschi, Filippo Dragoni, Elisabetta Schiaroli, et al.
Viruses (2022) Vol. 14, Iss. 7, pp. 1374-1374
Open Access | Times Cited: 21
Lia Fiaschi, Filippo Dragoni, Elisabetta Schiaroli, et al.
Viruses (2022) Vol. 14, Iss. 7, pp. 1374-1374
Open Access | Times Cited: 21
Showing 21 citing articles:
Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants
Jun‐Hyung Cho, Younmin Shin, Jeong‐Sun Yang, et al.
Antiviral Research (2023) Vol. 214, pp. 105609-105609
Open Access | Times Cited: 20
Jun‐Hyung Cho, Younmin Shin, Jeong‐Sun Yang, et al.
Antiviral Research (2023) Vol. 214, pp. 105609-105609
Open Access | Times Cited: 20
HIV and COVID-19 Co-Infection: Epidemiology, Clinical Characteristics, and Treatment
Dimitris Basoulis, Elpida Mastrogianni, Pantazis-Michail Voutsinas, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 577-577
Open Access | Times Cited: 18
Dimitris Basoulis, Elpida Mastrogianni, Pantazis-Michail Voutsinas, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 577-577
Open Access | Times Cited: 18
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study
Yoseph Caraco, Matthew G. Johnson, Joseph A. Chiarappa, et al.
Clinical Trials (2025)
Closed Access
Yoseph Caraco, Matthew G. Johnson, Joseph A. Chiarappa, et al.
Clinical Trials (2025)
Closed Access
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study
Samuel M. Brown, Morgan J. Katz, Adit A. Ginde, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 4, pp. 1189-1203
Open Access | Times Cited: 12
Samuel M. Brown, Morgan J. Katz, Adit A. Ginde, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 4, pp. 1189-1203
Open Access | Times Cited: 12
Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients
Paweł Poznański, Hanna Augustyniak‐Bartosik, Anna Magiera-Żak, et al.
Viruses (2022) Vol. 14, Iss. 10, pp. 2224-2224
Open Access | Times Cited: 21
Paweł Poznański, Hanna Augustyniak‐Bartosik, Anna Magiera-Żak, et al.
Viruses (2022) Vol. 14, Iss. 10, pp. 2224-2224
Open Access | Times Cited: 21
Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
Benjamin Chen, Nina M. Haste, Nancy Binkin, et al.
PLoS ONE (2023) Vol. 18, Iss. 4, pp. e0275356-e0275356
Open Access | Times Cited: 10
Benjamin Chen, Nina M. Haste, Nancy Binkin, et al.
PLoS ONE (2023) Vol. 18, Iss. 4, pp. e0275356-e0275356
Open Access | Times Cited: 10
An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead
Mehdi Valipour, Hamid Irannejad, Hossein Keyvani
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 9, pp. 1248-1265
Open Access | Times Cited: 9
Mehdi Valipour, Hamid Irannejad, Hossein Keyvani
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 9, pp. 1248-1265
Open Access | Times Cited: 9
The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)
Pasquale Pagliano, Carmine Sellitto, Tiziana Ascione, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 12, pp. 1299-1311
Closed Access | Times Cited: 15
Pasquale Pagliano, Carmine Sellitto, Tiziana Ascione, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 12, pp. 1299-1311
Closed Access | Times Cited: 15
Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort
Jorge Calderón‐Parra, Pablo Guisado‐Vasco, Rocío Montejano-Sánchez, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 864-864
Open Access | Times Cited: 8
Jorge Calderón‐Parra, Pablo Guisado‐Vasco, Rocío Montejano-Sánchez, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 864-864
Open Access | Times Cited: 8
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
(2024)
Open Access | Times Cited: 2
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
(2024)
Open Access | Times Cited: 2
Outcomes of SARS‐CoV‐2 infection among lung transplant recipients: A single center retrospective study
Alessio Casutt, Matthaios Papadimitriou‐Olivgeris, Foteini Ioakeim, et al.
Transplant Infectious Disease (2023) Vol. 25, Iss. 1
Closed Access | Times Cited: 7
Alessio Casutt, Matthaios Papadimitriou‐Olivgeris, Foteini Ioakeim, et al.
Transplant Infectious Disease (2023) Vol. 25, Iss. 1
Closed Access | Times Cited: 7
Real World Effectiveness of Tixagevimab/cilgavimab (Evusheld) in the Omicron Era
Benjamin Chen, Nina M. Haste, Nancy Binkin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 9
Benjamin Chen, Nina M. Haste, Nancy Binkin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 9
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 168-168
Open Access | Times Cited: 1
Lia Fiaschi, Camilla Biba, Ilenia Varasi, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 168-168
Open Access | Times Cited: 1
Prevention and treatment strategies for kidney transplant recipients in the context of long-term existence of COVID-19
Zeyuan Zheng, Huimin Sun, Xiao Hu, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 1
Zeyuan Zheng, Huimin Sun, Xiao Hu, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 1
Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?
Renata Esposito, Davida Mirra, Liberata Sportiello, et al.
Biomedicines (2022) Vol. 10, Iss. 11, pp. 2815-2815
Open Access | Times Cited: 7
Renata Esposito, Davida Mirra, Liberata Sportiello, et al.
Biomedicines (2022) Vol. 10, Iss. 11, pp. 2815-2815
Open Access | Times Cited: 7
Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review
Giacomo Casalini, Andrea Giacomelli, Spinello Antinori
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 12, pp. 1483-1494
Closed Access | Times Cited: 6
Giacomo Casalini, Andrea Giacomelli, Spinello Antinori
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 12, pp. 1483-1494
Closed Access | Times Cited: 6
Real world effectiveness of sotrovimab in preventing COVID-19–related hospitalisation or death in patients infected with Omicron BA.2
Alwaleed Behzad, Aamal Mohamed, Ahmed Ali, et al.
Journal of Infection and Public Health (2023) Vol. 17, Iss. 2, pp. 315-320
Open Access | Times Cited: 3
Alwaleed Behzad, Aamal Mohamed, Ahmed Ali, et al.
Journal of Infection and Public Health (2023) Vol. 17, Iss. 2, pp. 315-320
Open Access | Times Cited: 3
Switching the three-component Biginelli-like reaction conditions for the regioselective synthesis of new 2-amino[1,2,4]triazolo[1,5-a]pyrimidines
Martina Pacetti, Maria Chiara Pismataro, Tommaso Felicetti, et al.
Organic & Biomolecular Chemistry (2023) Vol. 22, Iss. 4, pp. 767-783
Open Access | Times Cited: 3
Martina Pacetti, Maria Chiara Pismataro, Tommaso Felicetti, et al.
Organic & Biomolecular Chemistry (2023) Vol. 22, Iss. 4, pp. 767-783
Open Access | Times Cited: 3
A phase I/II study of adoptive SARS-CoV-2-specific T cells in immunocompromised hosts with or at risk of severe COVID-19 infection
Michaela Su-Fern Seng, King Pan Ng, Teck Guan Soh, et al.
Cytotherapy (2024) Vol. 26, Iss. 10, pp. 1170-1178
Open Access
Michaela Su-Fern Seng, King Pan Ng, Teck Guan Soh, et al.
Cytotherapy (2024) Vol. 26, Iss. 10, pp. 1170-1178
Open Access
Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
Gaetano Cicchitto, Lorena Cardillo, Davide Sequino, et al.
Viruses (2022) Vol. 15, Iss. 1, pp. 102-102
Open Access | Times Cited: 3
Gaetano Cicchitto, Lorena Cardillo, Davide Sequino, et al.
Viruses (2022) Vol. 15, Iss. 1, pp. 102-102
Open Access | Times Cited: 3
Interchangeability of the Assays Used to Assess the Activity of Anti-SARS-CoV-2 Monoclonal Antibodies
Brady T. Hickerson, A. M. Khalenkov, Tao Xie, et al.
Viruses (2023) Vol. 15, Iss. 8, pp. 1698-1698
Open Access | Times Cited: 1
Brady T. Hickerson, A. M. Khalenkov, Tao Xie, et al.
Viruses (2023) Vol. 15, Iss. 8, pp. 1698-1698
Open Access | Times Cited: 1
A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases
R. Leonard, Rao Vn, Alexandria Bartlett, et al.
Journal of Virology (2023) Vol. 97, Iss. 8
Open Access
R. Leonard, Rao Vn, Alexandria Bartlett, et al.
Journal of Virology (2023) Vol. 97, Iss. 8
Open Access
